Heart Disease News and Research

Latest Heart Disease News and Research

Trauma, infection link with stroke seen in children

Research shows that trauma and acute infection are significant risk factors for arterial ischemic stroke in children.

8 Jan 2013

Contingency management benefits drug-dependent mental health patients

Contingency management significantly reduces stimulant drug use in dependent patients with serious mental illnesses, researchers report.

8 Jan 2013

Genomic and cellular solutions to be featured by Beckman Coulter Life Sciences at SLAS2013

Bringing together genomic and cellular sample preparation with integrated solutions to highlight their Automation with a Human Touch theme.

From Beckman Coulter Life Sciences - Automation and Genomics 8 Jan 2013

Esperion reports positive results from ETC-1002 Phase 2 clinical trial on type 2 diabetes

Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo.

8 Jan 2013

Thoratec to start REVIVE-IT study using HeartMate II Left Ventricular Assist System

Thoratec Corporation, a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that the U.S. Food and Drug Administration has granted an Investigational Device Exemption to commence the REVIVE-IT study utilizing the HeartMate II Left Ventricular Assist System.

8 Jan 2013

State roundup: Mo. lawmakers look to cap malpractice awards

A selection of health policy stories from California, Minnesota, Missouri, New York, Texas, Illinois and North Carolina.

8 Jan 2013

Spectrum Pharmaceuticals reveals positive RenaZorb Phase 1 clinical trial results

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced positive, statistically significant data from the Company's Phase 1 clinical trial evaluating the safety and tolerability of RenaZorb (also referred to as SPI-014) in healthy volunteers.

8 Jan 2013

Dementia diagnosis: an interview with Dr Andrew Blackwell, Chief Scientific Officer, Cambridge Cognition

Dementia is a huge public health problem, affecting about 800,000 people in the UK and 36 million people around the world.

8 Jan 2013

EHR implementation with technical support can improve patient care in small physician practices: Study

The relationship between a physician practice's adoption of electronic health records (EHR) and quality improvements in patient care remains unclear.

7 Jan 2013

Shoulder complaint linked to diabetes diagnosis

Study findings confirm suspicions that patients with diabetes have an increased risk for adhesive capsulitis of the shoulder.

7 Jan 2013

Vaccine gives HIV patients a long-term boost

A functional cure for HIV-1 seems feasible after research shows that an immunotherapeutic vaccine demonstrated long-term efficacy at reducing viral load when administered to patients in the early stages of disease.

7 Jan 2013

Real life experience of defibrillators lives up to clinical trial expectations

There is no significant difference in survival between clinical trial patients who receive an implantable cardioverter and clinical registry patients who receive a primary prevention ICD, researchers suggest.

7 Jan 2013

Merck’s resubmission of the NDA for suggammadex sodium injection accepted for review by the FDA

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the resubmission of the New Drug Application (NDA) for sugammadex sodium injection has been accepted for review by the U.S. Food and Drug Administration (FDA). Merck expects the FDA’s review to be completed in the first half of 2013.

7 Jan 2013

Industry sponsored drug and device studies: an interview with Professor Lisa Bero

Our review included analyses of drug and device studies conducted in humans. The drugs or devices could be compared to placebo or sham treatments, or other effective treatments. The drugs and devices examined for this review are used for a wide variety of clinical conditions, including cardiovascular and psychiatric diseases.

7 Jan 2013

Edison Pharmaceuticals to commence EPI-743 phase 2B Friedreich's ataxia study

Edison Pharmaceuticals today announced the initiation of a phase 2B study entitled, "Safety and Efficacy Study of EPI-743 on Visual Function in Patients with Friedreich's Ataxia."

7 Jan 2013

Virtual patient can help future physicians more comfortable and capable assessing suicide risk

A virtual patient named Denise may help future physicians feel more comfortable and capable assessing suicide risk.

7 Jan 2013

HHS gives 7 states the go-ahead to create health exchanges

So far, the Obama administration has approved the health exchange blueprints submitted by 17 states and the District of Columbia. And, the most recent set includes both red states, including Utah, and blue states.

7 Jan 2013

Rhythm commences RM-493 Phase 2 trial in obesity

Rhythm announced today the initiation of a Phase 2 clinical trial with RM-493, the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of obesity.

7 Jan 2013

PharmaIN receives FDA orphan-drug designation for terlipressin to treat ascites

PharmaIN Corporation and LAT Pharma LLC today announced that the US Food and Drug Administration (FDA) has granted their request for orphan-drug designation for terlipressin for the treatment of ascites due to all etiologies except for cancer.

7 Jan 2013

TRIP-Br2 plays a major role in energy metabolism and fat storage

As part of their ongoing research on the physiologic factors that contribute to the development of obesity, Joslin Diabetes Center scientists have identified a cell cycle transcriptional co-regulator - TRIP-Br2 - that plays a major role in energy metabolism and fat storage.

6 Jan 2013

Heart Disease News and Research

Latest Heart Disease News and Research

Trauma, infection link with stroke seen in children

Contingency management benefits drug-dependent mental health patients

Genomic and cellular solutions to be featured by Beckman Coulter Life Sciences at SLAS2013

Esperion reports positive results from ETC-1002 Phase 2 clinical trial on type 2 diabetes

Thoratec to start REVIVE-IT study using HeartMate II Left Ventricular Assist System

State roundup: Mo. lawmakers look to cap malpractice awards

Spectrum Pharmaceuticals reveals positive RenaZorb Phase 1 clinical trial results

Dementia diagnosis: an interview with Dr Andrew Blackwell, Chief Scientific Officer, Cambridge Cognition

EHR implementation with technical support can improve patient care in small physician practices: Study

Shoulder complaint linked to diabetes diagnosis

Vaccine gives HIV patients a long-term boost

Real life experience of defibrillators lives up to clinical trial expectations

Merck’s resubmission of the NDA for suggammadex sodium injection accepted for review by the FDA

Industry sponsored drug and device studies: an interview with Professor Lisa Bero

Edison Pharmaceuticals to commence EPI-743 phase 2B Friedreich's ataxia study

Virtual patient can help future physicians more comfortable and capable assessing suicide risk

HHS gives 7 states the go-ahead to create health exchanges

Rhythm commences RM-493 Phase 2 trial in obesity

PharmaIN receives FDA orphan-drug designation for terlipressin to treat ascites

TRIP-Br2 plays a major role in energy metabolism and fat storage

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Heart Disease News and Research

Latest Heart Disease News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in